Abstract
High-specific-activity I-131-MIBG (Azedra) is the only Food and Drug Administration-approved therapy for metastatic pheochromocytomas and paragangliom......
小提示：本篇文献需要登录阅读全文，点击跳转登录
Full Text Link
